Heptares
1-3 Burtonhole Lane, Mill Hill
London
NW7 1AD
United Kingdom
Tel: 44-0-20-8906-7100
84 articles about Heptares
-
Heptares Scientists Solve Structure Of CCR9 Chemokine Receptor Offering Unique Opportunity To Apply Structure-Based Design Across Chemokine Receptor Family
12/8/2016
-
Heptares To Acquire G7 Therapeutics AG To Extend Leadership In GPCR-Focused Drug Discovery And Development
11/30/2016
-
Sosei Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders
11/10/2016
-
Sosei Group Corporation Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders
11/10/2016
-
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC
7/6/2016
-
Heptares And Leadxpro Enter Collaboration On Powerful New Approaches To GPCR Structure Determination For Drug Discovery
6/29/2016
-
Heptares Chief Scientific Officer And Co-Founder - Dr Fiona Marshall - Elected As A Fellow Of The Academy of Medical Sciences
4/28/2016
-
Heptares Scientists Solve Structures Of GLP-1 And Glucagon Receptors Enabling Structure-Based Design For Metabolic Disease
4/25/2016
-
Kymab And Heptares Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Antibody Therapeutics
4/18/2016
-
A Day After The Pfizer-Allergan Deal Dies, Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares
4/11/2016
-
Heptares Joins Pharma Consortium Applying State Of The Art Cryo-Electron Microscopy To Advance Structure Based Drug Discovery
4/4/2016
-
Sosei Subsidiary Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1Receptor Agonist For Improving Cognition In Dementia And Schizophrenia
2/10/2016
-
Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Dementia And Schizophrenia
2/10/2016
-
Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme For Industry And Academia Focused On G Protein-Coupled Receptors (GPCRS)
2/2/2016
-
Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei
11/30/2015
-
Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Focused On GPCR Targets Across Multiple Therapeutic Areas
11/30/2015
-
Sosei Group Corporation Subsidiary Heptares Awarded $5.5 Million Research & Development Grant From National Institute on Drug Abuse (NIDA)
9/28/2015
-
Heptares Awarded $5.5 Million Research & Development Grant From The U.S. National Institute on Drug Abuse (NIDA)
9/28/2015
-
AstraZeneca PLC Emphasizes Immuno-Oncology with $510 Million+ Deal With Heptares
8/7/2015
-
Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease
6/17/2015